Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6…
MALVERN, Pa., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused…
HUNTSVILLE, AL, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing…
Burlington, Ontario--(Newsfile Corp. - December 10, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") today announced that…
The strategic partnership combines Dotmatics' deep expertise in scientific software with Databricks data intelligence expertise An upcoming webinar with Databricks…
Based on more than six months of additional monitoring, data show continued improvement in overall survival (OS) in intent-to-treat (ITT)…
Patented Technology Ensures Chain of Custody, Climate Control and Seamless Integration with Robots and Drones INDIANAPOLIS, Dec. 9, 2024 /PRNewswire/…
FORT LAUDERDALE, FL / ACCESSWIRE / December 9, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering…
The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg, without dose-limiting toxicity or evidence of cytokine release…
With most of Evaxion’s strategic milestones for 2024 now successfully achieved, the company announces milestones for 2025The 2025 key milestones…